SUNNYVALE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that posters related to PCI-24781 and PCI-32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, LA.
A material clinical update relating to both the PCI-24781 (HDAC Inhibitor) and PCI-32765 (BTK Inhibitor) programs will be presented at 6pm-8pm EST on Sunday, December 6, 2009 and Monday, December 7, 2009, respectively. The Company plans to issue a press release and hold a conference call related to the above items on December 8, 2009.
Poster details are as follows:
Title: Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma
Date / Time: Sunday, December 6, 2009, 6:00PM-8:00PM Location: Hall E (Ernest N. Morial Convention Center) Poster Board II-702 Poster Session: Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models Poster II Primary presenter: Dr. Andrew Evens, Northwestern University
PCI-24781 is a novel oral pan-HDACi with potent preclinical anti-tumor activity in lymphoma cell lines and models and has previously demonstrated safety and clinical benefit in solid cancers. PCI-24781 is a well tolerated pan-HDACi, including complete absence of prolonged QT abnormalities. Preliminary clinical benefit in heavily pre-treated relapsed/refractory lymphoma patients was documented in the phase I portion of this study as described in the published abstract. Twelve patients were evaluable for response. Two confirmed responses have been seen (1 complete remission, 1 partial remission), while six patien
|SOURCE Pharmacyclics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved